In addition, trastuzumab blocks TGF-β-stimulated Rac1 activation in the HER2-overexpessing cells, which suggests that HER2 and TGF-β crosstalk with each other to regulate tumor cell motility [184]. The gene discussed is TGFB1; the disease is neoplasm.